Significance of neutralizing antibodies in COVID-19 therapy: progress and prospect

doi:10.5246/jcps.2021.02.008

Abstract

Abstract:

SARS-CoV-2 infection is a serious threat to human life and health all over the world, and COVID-19 is a global epidemic caused by SARS-CoV-2 infection. SARS-CoV-2 is highly infectious, strange and variable. Therefore, the treatment of COVID-19 must be urgent and targeted. However, vaccines and currently used drugs generally do not have the above-mentioned characteristics. Although convalescent plasma of COVID-19 has shown a clinical application value in the emergency treatment of critical patients, it shows great limitations. All human recombinant multivalent neutralizing nano-antibodies may meet the deficiency of COVID-19 therapy. Gene engineering technologies have been used to develop specific neutralizing antibody (nAB) drugs for the treatment of COVID-19 worldwide. Some of the candidate nAB drugs have been entered the clinical trials and can be used for the therapy of COVID-19 shortly. In the present review, we studied and analyzed nABs for the treatment of COVID-19 and the progress and prospect from the following five aspects: 1) The biological and clinical characteristics of SARS-CoV-2 infection; 2) The feasibility of plasma therapy for convalescents with COVID-19; 3) The technical routes of developing nAb drugs; 4) The current status of developing global COVID-19 antibodies; 5) The difficulties and clinical use.

Key words: SARS-CoV-2, Neutralizing antibody (nAB), COVID-19

Supporting:

Zeqi Zhou, Xiangbin Wang, Xiqing Zhang, Yuan Zhang, Yankai Fu, Zhixian Wang, Yan Su, He Wang, Meng Xiao, Changxiao Liu. Significance of neutralizing antibodies in COVID-19 therapy: progress and prospect[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(2): 87-106.

Figures/Tables 5

References 54

[1]	Cao, Y.L.; Su, B.; Guo, X.H.; Sun, W.J.; Deng, Y.Q.; Bao, L.L.; Zhu, Q.Y.; Zhang, X.; Zheng, Y.H.; Geng, C.Y.; Chai, X.R.; He, R.S.; Li, X.F.; Lv, Q.; Zhu, H.; Deng, W.; Xu, Y.F.; Wang, Y.J.; Xie, X.S. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020, 182, 73–84.e16.
[2]	Zhou, Z.; Wang, X.; Fu, Y.; Zhang, X.; Liu, C. Letter to the editor: Neutralizing antibodies for the treatment of COVID-19. Acta Pharm. Sin. B. 2021, 11, 304–307.
[3]	Davies, N.G.; Barnard, R.C.; Jarvis, C.I.; Kucharski, A.J.; Munday, J.; Pearson, C.A.B. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. medRxiv. [Preprint.]. December. 24, 2020 [accessed 2020 December 30]. Available from: https://www.medrxiv.org/content/10.1101/2020.12.24. 20248822v1.
[4]	Zhu, N.; Zhang, D.Y.; Wang, W.L.; Li, X.W.; Yang, B.; Song, J.D.; Zhao, X.; Huang, B.Y.; Shi, W.F.; Lu, R.J.; Niu, P.H.; Zhan, F.X.; Ma, X.J.; Wang, D.Y.; Xu, W.B.; Wu, G.Z.; Gao, G.F.; Tan, W.J. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733.
[5]	Forster, P.; Forster, L.; Renfrew, C.; Forster, M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc. Natl. Acad. Sci. USA. 2020, 117, 9241–9243.
[6]	Liu, X.; Wang, X.J. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J. Genet. Genom. 2020, 47, 119–121.
[7]	Zou, X.; Chen, K.; Zou, J.W.; Han, P.Y.; Hao, J.; Han, Z.G. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 2020, 14, 185–192.
[8]	Wang, C.Y.; Li, W.T.; Drabek, D.; Okba, N.M.A.; van Haperen, R.; Osterhaus, A.D.M.E.; van Kuppeveld, F.J.M.; Haagmans, B.L.; Grosveld, F.; Bosch, B.J. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 2020, 11, 2251.
[9]	Jia, Y.; Shen, G.; Nguyen, S.; Zhang, Y.; Huang, K.S.; Ho, H.Y.; Hor, W.S.; Yang, C.H.; Bruning, John B. Li, C.D. Wang, W.L. Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity. bioRxiv. [Preprint.]. April 9, 2020 [accessed 2020 May 5] Available from: https://www.biorxiv.org/content/10.1101/2020.04.09.034942v2.
[10]	Shen, C.G.; Wang, Z.Q.; Zhao, F.; Yang, Y.; Li, J.X.; Yuan, J.; Wang, F.X.; Li, D.L.; Yang, M.H.; Xing, L.; Wei, J.L.; Xiao, H.X.; Yang, Y.; Qu, J.X.; Qing, L.; Chen, L.; Xu, Z.X.; Peng, L.; Li, Y.J.; Zheng, H.X.; Chen, F.; Huang, K.; Jiang, Y.J.; Liu, D.J.; Zhang, Z.; Liu, Y.X.; Liu, L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020, 323, 1582–1589.
[11]	General Office of the National Health Commission of PRC [Internet]. The Novel Coronavirus Pneumonia Convalescent Plasma Treatment Plan (Trial Version 2). [cited 2020 Feb 5]. Available from: http://www.gov.cn/zhengce/zhengceku/2020-03/05/content 5487145.htm.
[12]	Ravi, N.; Cortade, D.L.; Ng, E.; Wang, S.X. Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens. Bioelectron. 2020, 165, 112454.
[13]	Panda, S.; Ravindran, B. Isolation of human PBMCs. Bio-protocol. 2013, 3. DOI:10.21769/bioprotoc.323.
[14]	Gautam, A.; Donohue, D.; Hoke, A.; Miller, S.A.; Srinivasan, S.; Sowe, B.; Detwiler, L.; Lynch, J.; Levangie, M.; Hammamieh, R.; Jett, M. Investigating gene expression profiles of whole blood and peripheral blood mononuclear cells using multiple collection and processing methods. PLoS One. 2019, 14, e0225137.
[15]	Shui, X.; Huang, J.; Li, Y.H.; Xie, P.L.; Li, G.C. Construction and selection of human Fab antibody phage display library of liver cancer. Hybridoma(Larchmt). 2009, 28, 341–347.
[16]	Mulangu, S.; Dodd, L.E.; Davey, R.T.; Tshiani Mbaya, O.; Proschan, M.; Mukadi, D.; Lusakibanza Manzo, M.; Nzolo, D.; Tshomba Oloma, A.; Ibanda, A.; Ali, R.; Coulibaly, S.; Levine, A.C.; Grais, R.; Diaz, J.; Lane, H.C.; Muyembe-Tamfum, J.J.; Group, P.W.; Sivahera, B.; Camara, M.; Kojan, R.; Walker, R.; Dighero-Kemp, B.; Cao, H.; Mukumbayi, P.; Mbala-Kingebeni, P.; Ahuka, S.; Albert, S.; Bonnett, T.; Crozier, I.; Duvenhage, M.; Proffitt, C.; Teitelbaum, M.; Moench, T.; Aboulhab, J.; Barrett, K.; Cahill, K.; Cone, K.; Eckes, R.; Hensley, L.; Herpin, B.; Higgs, E.; Ledgerwood, J.; Pierson, J.; Smolskis, M.; Sow, Y.; Tierney, J.; Sivapalasingam, S.; Holman, W.; Gettinger, N.; Vallée, D.; Nordwall, J.; Team, P.C.S. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 2019, 381, 2293–2303.
[17]	Levine, M.M. Monoclonal antibody therapy for Ebola virus disease. N. Engl. J. Med. 2019, 381, 2365–2366.
[18]	AstraZeneca [Internet]. Our priorities in responding to the COVID-19 outbreak. [cited 2020 Feb 5]. Available from: https://www.astrazeneca.com/media-centre/articles/2020/ our-update-on-COVID-19. html.
[19]	AstraZeneca [Internet]. Researching antibodies to target COVID-19. [cited 2020 Feb 5]. Available from: https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-COVID-19.html#!
[20]	Adaptive[Internet]. Adaptive Biotechnologies and Microsoft expand partnership to decode COVID-19 immune response and provide open data access. [cited 2020 Feb 5]. Available from:https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-and-microsoft-expand-partnership-decode.
[21]	Amgen [Internet]. Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19. [cited 2020 Feb 5]. Available from: https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-COVID-19/.
[22]	Prnasia [Internet]. Pharm Biotechnology and Vir Biotechnology have reached a global research agreement on novel Coronavirus Antibody. [cited 2020 Feb 5]. Available from: https://www.prnasia.com/story/273436-1.shtml.
[23]	GSK [Internet]. GSK and Vir Biotechnology enter collaboration to find coronavirus solutions. [cited 2020 Feb 5]. Available from:https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/.
[24]	Fierce [Internet]. Samsung scores $362M deal to help Vir scale up COVID-19 antibody production. [cited 2020 Feb 5]. Available from: https://www.fiercepharma.com/manufacturing/vir-inks-deal-samsung-to-scale-up-COVID-19-antibody-manufacturing.
[25]	Ju B.; Zhang Q.; Ge X.; Wang R.; Yu J.; Shan S. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. ChemRxiv. [Preprint.] March.21, 2020. [accessed 2020 April 5]. Available from: https://www.biorxiv.org/content/10.1101/2020.03.21.990770v2.
[26]	Briibio [Internet]. Tsinghua University -the Third People’s Hospital of Shenzhen Municipality of has established cooperation with Tengshengbo to jointly develop whole-human monoclonal neutralizing antibody against COVID-19. [cited 2020 Feb 5]. Available from: https://cn.briibio.com/news/57.html.
[27]	Junshipharma [Internet]. Junshi Biology and Institute of Microbiology, CAS. Jointly developed Novel Coronavirus Neutralizing Antibody. [cited 2020 Feb 5]. Available from: http://www.junshipharma.com/News.html.
[28]	Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; Chen, Z.; Guo, Y.; Zhang, J.; Li, Y.; Song, X.; Chen, Y.; Xia, L.; Fu, L.; Hou, L.; Xu, J.; Yu, C.; Li, J.; Zhou, Q.; Chen, W. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020, 369, 650–655.
[29]	Wang, Q.H.; Zhang, Y.F.; Wu, L.L.; Niu, S.; Song, C.L.; Zhang, Z.Y.; Lu, G.W.; Qiao, C.P.; Hu, Y.; Yuen, K.Y.; Wang, Q.S.; Zhou, H.; Yan, J.H.; Qi, J.X. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020, 181, 894–904.e9.
[30]	Watanabe, Y.; Allen, J.D.; Wrapp, D.; McLellan, J.S.; Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020, 369, 330–333.
[31]	Zhang, Y.; Zhao, W.J.; Mao, Y.H.; Wang, S.S.; Yang, H. Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins using high-resolution mass spectrometry. 2020.
[32]	Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; Chen, Z.; Guo, Y.; Zhang, J.; Li, Y.; Song, X.; Chen, Y.; Xia, L.; Fu, L.; Hou, L.; Xu, J.; Yu, C.; Li, J.; Zhou, Q.; Chen, W. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020, 369, 650–655.
[33]	Zhang, B.; Zhou, X.; Zhu, C.; Song, Y.; Feng, F.; Qiu, Y.; Feng, J.; Jia, Q.; Song, Q.; Zhu, B.; Wang, J. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci 2020, 7, 157.
[34]	Baxt, B.; Mason, P.W. Foot-and-mouth disease virus undergoes restricted replication in macrophage cell cultures following fc receptor-mediated adsorption. Virology. 1995, 207, 503–509.
[35]	Wang, S.; Peng, Y.; Wang, R.; Jiao, S.; Wang, M.; Huang, W.; Shan, C.; Jiang, W.; Li, Z.; Gu, C.; Chen, B.; Hu, X.; Yao, Y.; Min, J.; Zhang, H.; Chen, Y.; Gao, G.; Tang, P.; Li, G.; Wang, A.; Wang, L.; Zhang, J.; Chen, S.; Gui, X.; Yuan, Z.; Liu, D. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat. Commun. 2020, 11, 5752.
[36]	Wu, F.; Yan, R.; Liu, M.; Liu, Z.; Wang, Y.; Luan, D. Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis. medRxiv. [Preprint.]. October 13, 2020.[accessed 2020 October 30]. Available from: https://www.medrxiv.org/content/10.1101/ 2020.10.08.20209114v1.
[37]	Zhou, Y.J.; Liu, Z.Z.; Li, S.B.; Xu, W.; Zhang, Q.Q.; Silva, I.T.; Li, C.; Wu, Y.L.; Jiang, Q.L.; Liu, Z.M.; Wang, Q.J.; Guo, Y.; Wu, J.B.; Gu, C.J.; Cai, X.; Qu, D.; Mayer, C.T.; Wang, X.X.; Wang, Q. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021, 34, 108699.
[38]	Liu, Y.; Tuck Soh, W.; Tada, A.; Arakawa, A.; Matsuoka, S.; Nakayama, E. An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies. medRxiv. [Preprint.]. December 18, 2020. [accessed 2020 December 30]. Available from: https://www.biorxiv.org/content/10.1101/2020.12.18. 423358v1.
[39]	Li, D.; Edwards, R.; Manne, K.; Martinez, D.; Schäfer, A.; Munir Alam, S. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. medRxiv. [Preprint.]. January 02, 2021. [accessed 2020 January 30]. Available from: https://www.biorxiv.org/content/10.1101/2020.12.31. 424729v1.
[40]	Halstead, S.B.; Mahalingam, S.; Marovich, M.A.; Ubol, S.; Mosser, D.M. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 2010, 10, 712–722.
[41]	Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020, 20, 269–270.
[42]	Zhao, J.J.; Yuan, Q.; Wang, H.Y.; Liu, W.; Liao, X.J.; Su, Y.Y.; Wang, X.; Yuan, J.; Li, T.D.; Li, J.X.; Qian, S.; Hong, C.M.; Wang, F.X.; Liu, Y.X.; Wang, Z.Q.; He, Q.; Li, Z.Y.; He, B.; Zhang, T.Y.; Fu, Y.; Ge, S.X.; Liu, L.; Zhang, J.; Xia, N.S.; Zhang, Z. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin. Infect. Dis. 2020, 71, 2027–2034.
[43]	Liu, L.; Wei, Q.; Lin, Q.; Fang, J.; Wang, H.; Kwok, H.; Tang, H.; Nishiura, K.; Peng, J.; Tan, Z.; Wu, T.; Cheung, K.W.; Chan, K.H.; Alvarez, X.; Qin, C.; Lackner, A.; Perlman, S.; Yuen, K.Y.; Chen, Z. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019, 4. DOI:10.1172/jci.insight.123158.
[44]	Gao, Q.; Bao, L.L.; Mao, H.Y.; Wang, L.; Xu, K.W.; Yang, M.N.; Li, Y.J.; Zhu, L.; Wang, N.; Lv, Z.; Gao, H.; Ge, X.Q.; Kan, B.; Hu, Y.L.; Liu, J.N.; Cai, F.; Jiang, D.Y.; Yin, Y.H.; Qin, C.F.; Li, J.; Gong, X.J.; Lou, X.Y.; Shi, W.; Wu, D.D.; Zhang, H.M.; Zhu, L.; Deng, W.; Li, Y.R.; Lu, J.X.; Li, C.G.; Wang, X.X.; Yin, W.D.; Zhang, Y.J.; Qin, C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020, 369, 77–81.
[45]	Rogers, T.F.; Zhao, F.; Huang, D.; Beutler, N.; Burns, A.; He, W.T.; Limbo, O.; Smith, C.; Song, G.; Woehl, J.; Yang, L.; Abbott, R.K.; Callaghan, S.; Garcia, E.; Hurtado, J.; Parren, M.; Peng, L.; Ramirez, S.; Ricketts, J.; Ricciardi, M.J.; Rawlings, S.A.; Wu, N.C.; Yuan, M.; Smith, D.M.; Nemazee, D.; Teijaro, J.R.; Voss, J.E.; Wilson, I.A.; Andrabi, R.; Briney, B.; Landais, E.; Sok, D.; Jardine, J.G.; Burton, D.R. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020, 369, 956–963.
[46]	Cao, Y.L.; Su, B.; Guo, X.H.; Sun, W.J.; Deng, Y.Q.; Bao, L.L.; Zhu, Q.Y.; Zhang, X.; Zheng, Y.H.; Geng, C.Y.; Chai, X.R.; He, R.S.; Li, X.F.; Lv, Q.; Zhu, H.; Deng, W.; Xu, Y.F.; Wang, Y.J.; Xie, X.S. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020, 182, 73–84.e16.
[47]	Wu, Y.; Wang, F.; Shen, C.; Peng, W.; Li, D.; Zhao, C. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020, 368, 1274–1278.
[48]	Liu, X.; Gao, F.; Gou, L.; Chen, Y.; Gu, Y.; Ao, L. Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection. ChemRxiv. [Preprint.] May 04, 2020. [accessed 2020 June 14]. Available from: https://www.biorxiv.org/content/ 10.1101/2020.05.03.074914v2.
[49]	Brouwer, P.J.M.; Caniels, T.G.; van der Straten, K.; Snitselaar, J.L.; Aldon, Y.; Bangaru, S.; Torres, J.L.; Okba, N.M.A.; Claireaux, M.; Kerster, G.; Bentlage, A.E.H.; van Haaren, M.M.; Guerra, D.; Burger, J.A.; Schermer, E.E.; Verheul, K.D.; van der Velde, N.; van der Kooi, A.; van Schooten, J.; van Breemen, M.J.; Bijl, T.P.L.; Sliepen, K.; Aartse, A.; Derking, R.; Bontjer, I.; Kootstra, N.A.; Wiersinga, W.J.; Vidarsson, G.; Haagmans, B.L.; Ward, A.B.; de Bree, G.J.; Sanders, R.W.; van Gils, M.J. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020, 369, 643–650.
[50]	Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; Chen, Z.; Guo, Y.; Zhang, J.; Li, Y.; Song, X.; Chen, Y.; Xia, L.; Fu, L.; Hou, L.; Xu, J.; Yu, C.; Li, J.; Zhou, Q.; Chen, W. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020, 369, 650–655.
[51]	Wang, P.; Liu, L.; Nair, M.S.; Yin, M.T.; Luo, Y.; Wang, Q. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg. Microbes. Infect. 2020, 9, 2091–2093.
[52]	Liu, L.; Wang, P.; Nair, M.S.; Yu, J.; Rapp, M.; Wang, Q.; Luo, Y.; Chan, J.F.; Sahi, V.; Figueroa, A.; Guo, X.V.; Cerutti, G.; Bimela, J.; Gorman, J.; Zhou, T.; Chen, Z.; Yuen, K.Y.; Kwong, P.D.; Sodroski, J.G.; Yin, M.T.; Sheng, Z.; Huang, Y.; Shapiro, L.; Ho, D.D. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020, 584, 450–456.
[53]	Caifuhao [Internet]. US pauses Eli Lilly’s trial of a coronavirus antibody treatment over safety concerns. Health and Science, Oct 13, 2020. [cited 2020 Feb 5]. Available from: http://caifuhao.eastmoney.com/news/ 20201015093547254047210.
[54]	Sun, Y.P.; Ho, M. Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. Antibody Ther. 2020, 3, 246–256.